Casi Pharma

CASI Pharmaceuticals is a biopharma firm with a China–U.S. focus, advancing hematology/oncology therapeutics—EVOMELA, CNCT19 CAR‑T, BI‑1206 anti‑Fc?RIIB antibody, and CB‑5339 VCP/p97 inhibitor—in multiple phases.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 233
HQ: Beijing

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CASI	Casi Pharma Cap: 0.0B	EQUITY	NMS	USD	US14757U1097	Active	📈